Synthesis and Structural Analysis of Persuasive Antibacterial Agents and Enzyme Inhibitors Derived from 5-(1-(4-Tosyl)piperidin-4-yl)-1,3,4-oxadiazol-2-thiol

AZIZ-UR-REHMAN^{1,*}, ALMAS SATTAR¹, MUHAMMAD ATHAR ABBASI¹, SABAHAT Z. SIDDIQUI¹,
M. ARSLAN RAZA¹, MUHAMMAD ASHRAF², MUNIBAANUM NAZIR² and SYED ADNAN ALI SHAH³

¹Department of Chemistry, Government College University, Lahore-54000, Pakistan

²Department of Biochemistry and Biotechnology, The Islamia University of Bahawalpur, Bahawalpur-63100, Pakistan

³Faculty of Pharmacy and Atta-ur-Rahman Institute for Natural Products Discovery (AuRIns), Universiti Teknologi MARA, Puncak Alam Campus, 42300 Bandar Puncak Alam, Selangor Darul Ehsan, Malaysia

*Corresponding author: Tel: +92 42 111000010 Ext. 450; E-mail: azizryk@yahoo.com

Received: 17 June 2017;

Accepted: 30 September 2017;

Published online: 31 December 2017;

AJC-18688

Due to outstanding biological activities of 1,3,4-oxadiazole, a series of *S*-substituted derivatives of 5-[1-(4-tosyl)piperidin-4-yl]-1,3,4-oxadiazol-2-thiol (**5a-f**) was synthesized. The reaction of *p*-toluene sulfonyl chloride (**a**) with ethyl isonipecotatate (**b**) produced ethyl 1-(4-tosyl)piperidin-4-carboxylate (**1**) which was successively converted to 1-(4-tosyl)piperidin-4-carbohydrazide (**2**) by hydrazine and 5-[1-(4-tosyl)piperidin-4-yl]-1,3,4-oxadiazol-2-thiol (**3**) by CS₂ in the presence of KOH. The aimed compounds (**5a-f**) were synthesized by the reaction of compound **3** with different electrophiles in DMF using lithium hydride as catalyst. The structural confirmation was done by IR, ¹H NMR & EI-MS spectral analysis. The synthesized compounds were screened against α -glucosidase enzyme and five Gram bacterial strains.

Keywords: 1,3,4-Oxadiazole, α -Glucosidase, Antibacterial activity, Ethyl isonipecotatate, Toluenesulfonylchloride.

INTRODUCTION

Oxadiazoles specially 1,3,4-oxadiazole has gained huge concern which is evident by the literature review of previous fifteen years, during this era more than 2500 publications have been published [1]. 1,3,4-Oxadiazole moiety containing compounds have diverse range of biological activities [2] including ulcerogenic [3], hypolipidemic [4], cytotoxic [5], anesthetic [6], anti-inflammatory [7], vasodilatory [8], anticonvulsant [9], analgesic [10], antifungal [11], enzyme inhibition [12] and antimicrobial [13]. Among the molecules containing 1,3,4-oxadiazole, the derivatives of 1,3,4-oxadiazoles-2-thiones also called as mercapto-oxadiazoles have strong antimicrobial [14] and enzyme inhibition activities [15].

Considering the potent antimicrobial and enzyme inhibition activities of mercapto-oxadiazole, some of its derivatives were synthesized and screened against microbes along with some enzymes to evaluate their biological potential.

EXPERIMENTAL

Griffin and George melting point apparatus was used to determine the melting points of synthesized compounds in open capillary tube and were not corrected. Thin layer

chromatography (TLC) on pre-coated silica gel G-25-UV₂₅₄ plates was carried out to confirm purity of the synthesized compounds. The TLC for each compound was developed by using appropriate polarity solvent systems of *n*-hexane and ethyl acetate. All compounds gave single spot on TLC. Jasco-320-A spectrometer was used to obtain I.R spectra (wavenumber in cm⁻¹) of synthesized compounds with the help of KBr pellets method. Bruker spectrometer operating at 400 MHz was used to obtain NMR spectra of synthesized compounds in CDCl₃ solvent, chemical shifts are given in ppm. JMS-HX-110 spectrometer, with a data system was used to obtain mass spectra (EIMS).

Preparation of ethyl 1-(4-tosyl)piperidin-4-carboxylate (1): Ethyl isonipecotatate (**a**; 10 mL, 64.945 mmol) was poured in 35 mL distilled water in a 250 mL round bottom flask. *p*-Toluene sulfonyl chloride (**b**; 7.825 g, 64.945 mmol) was added pinch by pinch in about 20-25 min into the round bottom flask containing suspension of ethyl isonipecotatate in water. The pH of the solution was maintained at 9.0 by basic aqueous solution of 5 % Na₂CO₃. The reaction was stirred for 2-3 h. The progress and completion of reaction was monitored with the help of TLC. At the completion of reaction the pH of reaction mixture was adjusted using HCl (2 mL, 11 M) to 6.

The reaction was left for about 15 min. The precipitates of anticipated compound **1** were filtered and washed using cold distilled water.

Preparation of 1-(4-tosyl)piperidin-4-carbohydrazide (2): Ethyl 1-(4-tosyl)piperidin-4-carboxylate (**1**; 5.0 g, 16.07 mmol) was dissolved in 25 mL of methanol in 250 mL round bottom flask. Hydrazine hydrate (80 %, 15 mL) was poured slowly to reaction mixture and refluxed for 3-4 h and reaction progress was monitored by TLC. The white crystals of aimed compound **2** were obtained by evaporating extra solvent and adding excess of distilled water. The product was collected through filtration, washed with cold distilled water and dried for further use.

Preparation of 5-[1-(4-tosyl)piperidin-4-yl]-1,3,4-oxadiazol-2-thiol (3): 1-(4-Tosyl)piperidin-4-carbohydrazide (**2**; 4.0 g, 13.46 mmol) was dissolved in methanol (25 mL) in a 250 mL round bottom flask. Potassium hydroxide (0.75 g, 13.46 mmol) and carbon disulfide (1.3 mL, 26.92 mmol) was added to the reaction mixture. Reaction mixture was refluxed for 5-6 h and monitored to verify completion by TLC. At the completion of reaction, chilled distilled water (50 mL) was added to the reaction mixture and then acidified to pH 2-3 with dilute hydrochloric acid to get the solid precipitates. Off white precipitates of product **3** were filtered, washed with cold distilled water and dried.

General procedure for the synthesis of S-substituted derivatives of 3 (5a-f): 5-[1-(4-Tosyl)piperidin-4-yl]-1,3,4-oxadiazol-2-thiol (**3**; 0.0339 g, 0.1 mmol) was taken in round bottom flask (50 mL). *N,N*-Dimethyl formamide (DMF, 10 mL) was added to dissolve compound **3** followed by the addition of sodium hydride (0.0024 g, 0.1 mmol) at room temperature and stirred for 0.5 h. Then alkyl/aralkyl halides (**4a-f**), were added in an equimolar ratio to **3**. The mixture was stirred for 3-4 h. The progress of reaction was monitored with TLC till single spot. Distilled water was added to reaction mixture and products (**5a-f**) were recovered by filtration followed by washing and drying.

Ethyl 1-(4-tosyl)piperidin-4-carboxylate (1): White amorphous solid; Yield: 89 %; m.p.: 70-72 °C; m.f.: C₁₅H₂₁NO₄S; m.w.: 311; IR (KBr, $\nu_{\max}$, cm⁻¹): 3067 (C-H stretching of aromatic ring), 1732 (C=O stretching), 1531 (C=C aromatic stretching), 1335 (-SO₂- stretching), 1079 (C-O bond stretching); ¹H NMR (400 MHz, CDCl₃, δ , ppm): 7.62 (d, *J* = 8.0 Hz, 2H, H-2" & H-6"), 7.32 (d, *J* = 8.0 Hz, 2H, H-3" & H-5"), 3.98 (q, *J* = 7.2 Hz, 2H, O-CH₂), 3.71-3.68 (m, 2H, H_c-2' & H_c-6'), 2.73-2.62 (m, 1H, H-4'), 2.54-2.48 (m, 2H, H_a-2' & H_a-6'), 2.42 (s, 3H, CH₃-4"), 2.10-2.08 (m, 2H, H_c-3' & H_c-5'), 1.60-1.86 (m, 2H, H_a-3' & H_a-5'), 1.15 (t, *J* = 7.2 Hz, CH₃); EIMS (*m/z*): 311 [M]⁺, 266 [C₁₃H₁₆NO₃S]⁺, 238 [C₁₂H₁₆NO₂S]⁺, 184 [C₈H₁₀NO₂S]⁺, 170 [C₇H₈NO₂S]⁺, 155 [C₇H₇O₂S]⁺, 91 [C₇H₇]⁺.

1-(4-Tosyl)piperidin-4-carbohydrazide (2): White crystalline solid; Yield: 91 %; m.p.: 128-130 °C; m.f.: C₁₃H₁₉N₃O₃S; m.w.: 297; IR (KBr, $\nu_{\max}$, cm⁻¹): 3348 (N-H stretching), 3063 (C-H stretching of aromatic ring), 1682 (C=O stretching), 1534 (C=C aromatic stretching), 1339 (-SO₂- stretching); ¹H NMR (400 MHz, CDCl₃, δ , ppm): 7.61 (d, *J* = 8.0 Hz, 2H, H-2" & H-6"), 7.33 (d, *J* = 8.0 Hz, 2H, H-3" & H-5"), 3.72-3.69 (m, 2H, H_c-2' & H_c-6'), 2.73-2.62 (m, 1H, H-4'), 2.53-2.49 (m,

2H, H_c-2' & H_c-6'), 2.42 (s, 3H, CH₃-4"), 2.12-2.10 (m, 2H, H_c-3' & H_c-5'), 1.58-1.84 (m, 2H, H_a-3' & H_a-5'); EIMS (*m/z*): 297 [M]⁺, 266 [C₁₃H₁₆NO₃S]⁺, 238 [C₁₂H₁₆NO₂S]⁺, 184 [C₈H₁₀NO₂S]⁺, 170 [C₇H₈NO₂S]⁺, 155 [C₇H₇O₂S]⁺, 91 [C₇H₇]⁺.

5-[1-(4-Tosyl)piperidin-4-yl]-1,3,4-oxadiazol-2-thiol (3): White amorphous solid; Yield: 87 %; m.p.: 230-233 °C; m.f.: C₁₄H₁₇N₃O₃S₂; m.w.: 339; IR (KBr, $\nu_{\max}$, cm⁻¹): 3067 (C-H stretching of aromatic ring), 2522 (S-H bond stretching), 1641 (C=N stretching of oxadiazole ring), 1541 (C=C aromatic stretching), 1345 (-SO₂- stretching), 1249 & 1079 (C-O-C bond stretching); ¹H NMR (400 MHz, CDCl₃, δ , ppm): 7.63 (d, *J* = 8.0 Hz, 2H, H-2" & H-6"), 7.32 (d, *J* = 8.0 Hz, 2H, H-3" & H-5"), 3.71-3.68 (m, 2H, H_c-2' & H_c-6'), 2.74-2.63 (m, 1H, H-4'), 2.54-2.48 (m, 2H, H_a-2' & H_a-6'), 2.42 (s, 3H, CH₃-4"), 2.10-2.08 (m, 2H, H_c-3' & H_c-5'), 1.59-1.85 (m, 2H, H_a-3' & H_a-5'); EIMS (*m/z*): 339 [M]⁺, 266 [C₁₃H₁₆NO₃S]⁺, 238 [C₁₂H₁₆NO₂S]⁺, 184 [C₈H₁₀NO₂S]⁺, 170 [C₇H₈NO₂S]⁺, 155 [C₇H₇O₂S]⁺, 91 [C₇H₇]⁺.

4-[2-(Allylthio)-1,3,4-oxadiazol-5-yl]-1-(4-tosyl)piperidine (5a): Light yellow amorphous solid; Yield: 75 %; m.p.: 115-117 °C; m.f.: C₁₇H₂₁N₃O₃S₂; m.w.: 379; IR (KBr, $\nu_{\max}$, cm⁻¹): 3055 (C-H stretching of aromatic ring), 1648 (C=N stretching of oxadiazole ring), 1677 (C=C stretching of allyl), 1537 (C=C aromatic stretching), 1354 (-SO₂- stretching), 1257 & 1076 (C-O-C bond stretching); ¹H NMR (400 MHz, CDCl₃, δ , ppm): 7.63 (d, *J* = 8.0 Hz, 2H, H-2" & H-6"), 7.31 (d, *J* = 8.0 Hz, 2H, H-3" & H-5"), 5.97-5.88 (m, 1H, H-2'''), 5.33-5.29 (m, 1H, H_a-3'''), 5.17-5.12 (m, 1H, H_b-3'''), 3.81 (d, *J* = 6.8 Hz, 2H, CH₂-1'''), 2.87-2.81 (m, 2H, H_c-2' & H_c-6'), 2.86-2.81 (m, 1H, H-4'), 2.61-2.54 (m, 2H, H_a-2' & H_a-6'), 2.42 (s, 3H, CH₃-4"), 2.12-2.07 (m, 2H, H_c-3' & H_c-5'), 2.00-1.91 (m, 2H, H_a-3' & H_a-5'); EIMS (*m/z*): 379 [M]⁺, 266 [C₁₃H₁₆NO₃S]⁺, 238 [C₁₂H₁₆NO₂S]⁺, 184 [C₈H₁₀NO₂S]⁺, 170 [C₇H₈NO₂S]⁺, 155 [C₇H₇O₂S]⁺, 91 [C₇H₇]⁺, 83 [C₅H₉N]⁺, 41 [C₃H₅]⁺.

4-[2-(2-Chloroethylthio)-1,3,4-oxadiazol-5-yl]-1-(4-tosyl)piperidine (5b): Light yellow amorphous solid; Yield: 81 %; m.p.: 212-214 °C; m.f.: C₁₆H₂₀N₃O₃S₂Cl; m.w.: 401; IR (KBr, $\nu_{\max}$, cm⁻¹): 3062 (C-H stretching of aromatic ring), 1643 (C=N stretching of oxadiazole ring), 1533 (C=C aromatic stretching), 1335 (-SO₂- stretching), 1249 & 1079 (C-O-C bond stretching), 713 (C-Cl bond stretching); ¹H NMR (400 MHz, CDCl₃, δ , ppm): 7.63 (d, *J* = 8.0 Hz, 2H, H-2" & H-6"), 7.31 (d, *J* = 8.0 Hz, 2H, H-3" & H-5"), 3.81 (t, *J* = 7.2 Hz, 2H, H-2'''), 3.53 (t, *J* = 7.2 Hz, 2H, H-1'''), 3.31-3.26 (m, 2H, H_c-2' & H_c-6'), 2.87-2.80 (m, 1H, H-4'), 2.60-2.54 (m, 2H, H_a-2' & H_a-6'), 2.42 (s, 3H, CH₃-4"), 2.12-2.08 (m, 2H, H_c-3' & H_c-5'), 2.01-1.94 (m, 2H, H_a-3' & H_a-5'); EIMS (*m/z*): 403 [M+2]⁺, 401 [M]⁺, 266 [C₁₃H₁₆NO₃S]⁺, 238 [C₁₂H₁₆NO₂S]⁺, 184 [C₈H₁₀NO₂S]⁺, 170 [C₇H₈NO₂S]⁺, 155 [C₇H₇O₂S]⁺, 91 [C₇H₇]⁺, 83 [C₅H₉N]⁺, 63 [C₂H₄Cl]⁺.

4-[2-(2-Bromoethylthio)-1,3,4-oxadiazol-5-yl]-1-(4-tosyl)piperidine (5c): Fluffy white solid; Yield: 81 %; m.p.: 223-225 °C; m.f.: C₁₆H₂₀N₃O₃S₂Br; m.w.: 445; IR (KBr, $\nu_{\max}$, cm⁻¹): 3061 (C-H stretching of aromatic ring), 1642 (C=N stretching of oxadiazole ring), 1529 (C=C aromatic stretching), 1331 (-SO₂- stretching), 1247 & 1077 (C-O-C bond stretching), 634 (C-Br bond stretching); ¹H NMR (400 MHz, CDCl₃, δ , ppm): 7.59 (d, *J* = 8.0 Hz, 2H, H-2" & H-6"), 7.29 (d, *J* = 8.0

Hz, 2H, H-3" & H-5"), 3.71 (t, $J = 7.2$ Hz, 2H, H-2"), 3.43 (t, $J = 7.2$ Hz, 2H, H-1"), 3.32-3.27 (m, 2H, H_c-2' & H_c-6'), 2.87-2.80 (m, 1H, H-4'), 2.60-2.54 (m, 2H, H_a-2' & H_a-6'), 2.42 (s, 3H, CH₃-4"), 2.09-2.07 (m, 2H, H_c-3' & H_c-5'), 2.00-1.93 (m, 2H, H_a-3' & H_a-5'); EIMS (m/z): 447 [M+2]⁺, 445 [M]⁺, 266 [C₁₃H₁₆NO₃S]⁺, 238 [C₁₂H₁₆NO₂S]⁺, 184 [C₈H₁₀NO₂S]⁺, 170 [C₇H₈NO₂S]⁺, 155 [C₇H₇O₂S]⁺, 107 [C₂H₄Br]⁺, 91 [C₇H₇]⁺, 83 [C₅H₉N]⁺.

4-[2-(2-Phenylethylthio)-1,3,4-oxadiazol-5-yl]-1-(4-tosyl)piperidine (5d): Fluffy white solid; Yield: 85 %; m.p.: 120-122 °C; m.f.: C₂₂H₂₅N₃O₃S₂; m.w.: 443; IR (KBr, $\nu_{\max}$, cm⁻¹): 3046 (C-H stretching of aromatic ring), 1657 (C=N stretching of oxadiazole ring), 1541 (C=C aromatic stretching), 1343 (-SO₂- stretching), 1242 & 1083 (C-O-C bond stretching); ¹H NMR (400 MHz, CDCl₃, δ , ppm): 7.63 (d, $J = 8.0$ Hz, 2H, H-2" & H-6"), 7.31 (d, $J = 7.6$ Hz, 2H, H-3" & H-5"), 7.37-7.25 (m, 5H, H-2" to H-6"), 4.39 (t, $J = 5.6$ Hz, 2H, CH₂-7"), 3.89 (t, $J = 5.6$ Hz, 2H, CH₂-8"), 3.66-3.63 (m, 2H, H_c-2' & H_c-6'), 2.84-2.79 (m, 1H, H-4'), 2.60-2.53 (m, 2H, H_a-2' & H_a-6'), 2.42 (s, 3H, CH₃-4"), 2.10-2.05 (m, 2H, H_c-3' & H_c-5'), 1.98-1.89 (m, 2H, H_a-3' & H_a-5'); EIMS (m/z): 443 [M]⁺, 266 [C₁₃H₁₆NO₃S]⁺, 238 [C₁₂H₁₆NO₂S]⁺, 184 [C₈H₁₀NO₂S]⁺, 170 [C₇H₈NO₂S]⁺, 155 [C₇H₇O₂S]⁺, 105 [C₈H₉]⁺, 91 [C₇H₇]⁺, 83 [C₅H₉N]⁺, 77 [C₆H₅]⁺, 51 [C₄H₃]⁺.

4-[2-(3-Phenylpropylthio)-1,3,4-oxadiazol-5-yl]-1-(4-tosyl)piperidine (5e): White crystalline solid; Yield: 85 %; m.p.: 115-117 °C; m.f.: C₂₃H₂₇N₃O₃S₂; m.w.: 457; IR (KBr, $\nu_{\max}$, cm⁻¹): 3041 (C-H stretching of aromatic ring), 1652 (C=N stretching of oxadiazole ring), 1539 (C=C aromatic stretching), 1341 (-SO₂- stretching), 1241 & 1082 (C-O-C bond stretching); ¹H NMR (400 MHz, CDCl₃, δ , ppm): 7.63 (d, $J = 8.0$ Hz, 2H, H-2" & H-6"), 7.31 (d, $J = 7.6$ Hz, 2H, H-3" & H-5"), 7.37-7.25 (m, 5H, H-2" to H-6"), 4.45 (t, $J = 5.6$ Hz, 2H, CH₂-7"), 3.90 (t, $J = 5.6$ Hz, 2H, CH₂-9"), 3.79-3.76 (m, 2H, CH₂-8"), 3.66-3.63 (m, 2H, H_c-2' & H_c-6'), 2.84-2.79 (m, 1H, H-4'), 2.60-2.53 (m, 2H, H_a-2' & H_a-6'), 2.42 (s, 3H, CH₃-4"), 2.10-2.05 (m, 2H, H_c-3' & H_c-5'), 1.98-1.89 (m, 2H, H_a-3' & H_a-5'); EIMS (m/z): 457 [M]⁺, 266 [C₁₃H₁₆NO₃S]⁺, 238 [C₁₂H₁₆NO₂S]⁺, 184 [C₈H₁₀NO₂S]⁺, 170 [C₇H₈NO₂S]⁺, 155 [C₇H₇O₂S]⁺, 119 [C₉H₁₁]⁺, 91 [C₇H₇]⁺, 83 [C₅H₉N]⁺, 77 [C₆H₅]⁺, 65 [C₅H₅]⁺, 51 [C₄H₃]⁺.

4-[2-((1,3-Dioxolan-2-yl)methylthio)-1,3,4-oxadiazol-5-yl]-1-(4-tosyl)piperidine (5f): White powder solid; Yield: 81 %; m.p.: 130-132 °C; m.f.: C₁₈H₂₃N₃O₅S₂; m.w.: 425; IR

(KBr, $\nu_{\max}$, cm⁻¹): 3065 (C-H stretching of aromatic ring), 1638 (C=N stretching of oxadiazole ring), 1534 (C=C aromatic stretching), 1335 (-SO₂- stretching), 1248 & 1078 (C-O-C bond stretching); ¹H NMR (400 MHz, CDCl₃, δ , ppm): 7.63 (d, $J = 8.0$ Hz, 2H, H-2" & H-6"), 7.32 (d, $J = 8.0$ Hz, 2H, H-3" & H-5"), 5.10 (t, $J = 3.60$ Hz, 1H, H-5"), 4.15-4.12 (m, 4H, H-2" & H-3"), 3.71-3.68 (m, 2H, H_c-2' & H_c-6'), 3.33 (d, $J = 3.2$ Hz, 2H, CH₂-6"), 2.74-2.63 (m, 1H, H-4') 2.54-2.48 (m, 2H, H_a-2' & H_a-6'), 2.42 (s, 3H, CH₃-4"), 2.11-2.09 (m, 2H, H_c-3' & H_c-5'), 1.59-1.85 (m, 2H, H_a-3' & H_a-5'); EIMS (m/z): 425 [M]⁺, 266 [C₁₃H₁₆NO₃S]⁺, 238 [C₁₂H₁₆NO₂S]⁺, 184 [C₈H₁₀NO₂S]⁺, 170 [C₇H₈NO₂S]⁺, 155 [C₇H₇O₂S]⁺, 91 [C₇H₇]⁺, 87 [C₄H₇O₂]⁺, 83 [C₅H₉N]⁺, 73 [C₃H₅O₂]⁺.

α -Glucosidase enzyme inhibition assay: The α -glucosidase inhibition activity was assayed according to Chapdelaine *et al.* [16] method with a little modification. The variation in absorbance before and after the addition of test compound in prepared enzyme solution was noted.

Antibacterial activity assay: The antibacterial activity was performed in sterile 96-wells microplates under aseptic environments. The method is based on the principle that microbial cell number increases as the microbial growth proceeds in a log phase of growth which results in increased absorbance of broth medium [17].

Statistical analysis: All the measurements were performed in triplicate and statistical analysis was obtained from Microsoft Excel 2010. The results are presented as mean $\pm$ SEM. The MIC (minimum inhibitory concentration, measured with suitable dilutions, 5-30 μ g/well) and IC₅₀ (50 % inhibitory concentration) were calculated using EZ - Fitz Perrella Scientific Inc. Amherst USA software.

RESULTS AND DISCUSSION

The aim of present study was to synthesize *S*-substituted derivatives of 1,3,4-oxadiazoles-2-thiones containing piperidine and *p*-toluene sulfonyl moieties along with their biological screening including enzyme inhibition and antibacterial activity. A series of six compounds **5a-f** was synthesized according to **Scheme-I**.

The compound **5a** was prepared as light yellow amorphous solid. The molecular formula, C₁₇H₂₁N₃O₃S₂, was established from molecular ion peak at m/z 379 in EIMS and by counting protons from ¹H NMR spectrum. The IR spectrum gave peaks at 3055, 1648, 1677, 1537, 1354, 1257 and 1076 which were

Scheme-I: Outline for the synthesis of *S*-substituted derivatives of 5-(1-(4-tosyl)piperidin-4-yl)-1,3,4-oxadiazol-2-thiol (**5a-f**)

assigned to C-H (stretching of aromatic ring), C=N (stretching of oxadiazole ring), C=C (stretching of allyl), C=C (aromatic stretching), -SO₂- (stretching) and C-O-C (bond stretching of oxadiazole) respectively. In EIMS spectrum, the peak at m/z 266 showed the removal of allyl sulfide group along with partial removal of oxadiazole ring from **5a**, peak at m/z 155 showed the presence of *p*-toluenesulfonyl group and peak at m/z 83 indicated the presence of piperidine moiety. The other prominent fragments are given in Fig. 1. In the aromatic region of ¹H NMR signals appeared at δ 7.63 (d, J = 8.0 Hz, 2H, H-2" & H-6") and 7.31 (d, J = 8.0 Hz, 2H, H-3" & H-5") indicating the paradisubstituted benzene ring, *p*-toluene sulfonyl moiety. The signals appearing at δ 5.97-5.88 (m, 1H, H-2'''), 5.33-5.29 (m, 1H, H_a-3'''), 5.17-5.12 (m, 1H, H_b-3''') and 3.81 (d, J = 6.8 Hz, 2H, CH₂-1''') were assigned to *S*-substituted allyl group. The signals resonating at δ 2.87-2.81 (m, 2H, H_e-2' & H_e-6'), 2.86-2.81 (m, 1H, H-4'), 2.61-2.54 (m, 2H, H_a-2' & H_a-6'), 2.12-2.07 (m, 2H, H_e-3' & H_e-5') and 2.00-1.91 (m, 2H, H_a-3' & H_a-5') were assigned to piperidine moiety. The singlet at δ 2.42 (s, 3H, CH₃-4'') indicated the presence of methyl substituent of toluene sulfonyl ring. The structures of other compounds were determined similarly using EIMS, IR and ¹H NMR techniques.

Enzyme inhibition activity: The screening of synthesized compounds against α -glucosidase enzyme revealed that these compounds are weakly active against α -glucosidase. The results are given in Table-1. It is evident from the tabulated data of enzyme inhibition that compound **5b** was the most potent with IC₅₀ value of 190.23 $\pm$ 0.13 μ M with respect to that of acarbose as 38.25 $\pm$ 0.12 μ M, the reference standard. The compound

5a showed no activity against this enzyme. The somewhat better activity of **5b** can be attributed to chloroethyl substituent attached to sulfur of 5-[1-(4-tosyl)piperidin-4-yl]-1,3,4-oxadiazol-2-thiol. The overall ascending order of inhibition of synthesized compounds is **5f** < **5e** < **5c** < **5d** < **5b**.

TABLE-1
ENZYME INHIBITION ACTIVITY
AGAINST α -GLUCOSIDASE ENZYME

Compound	α -Glucosidase	
	Inhibition (%) at 0.5 mM	IC ₅₀ (μ M)
5a	32.15 $\pm$ 0.29	-
5b	71.34 $\pm$ 0.43	190.23 $\pm$ 0.13
5c	84.43 $\pm$ 0.25	316.49 $\pm$ 0.11
5d	88.15 $\pm$ 0.42	297.92 $\pm$ 0.19
5e	61.33 $\pm$ 0.31	318.57 $\pm$ 0.11
5f	84.46 $\pm$ 0.16	321.43 $\pm$ 0.14
Control (acarbose)	92.23 $\pm$ 0.14	38.25 $\pm$ 0.12

Antibacterial activity: The results of antibacterial activity against Gram-bacteria using ciprofloxacin as reference standard are given in Tables 2 and 3. In this study five bacterial strains were included, two Gram-positive and three Gram-negative. All the compounds showed strong to moderate activity. The compounds **5b** and **5e** showed inhibition of all microbes under consideration. The highest potency of compounds **5b** and **5e** was against *Bacillus subtilis* and *Salmonella typhi*, respectively. The compound **5a** inhibited the growth of all microbes under study except that of *Staphylococcus aureus*. It was also proved most potent against *Escherichia coli* with MIC value of 9.90 $\pm$ 0.13 μ M whereas that of standard

Fig. 1. Mass fragmentation pattern of compound **5a**

TABLE-2
 PERCENTAGE INHIBITION OF ANTIBACTERIAL ACTIVITY OF SYNTHESIZED COMPOUNDS

Compounds	Inhibition (%)				
	<i>Salmonella typhi</i> (-)	<i>Escherichia coli</i> (-)	<i>Pseudomonas aeruginosa</i> (-)	<i>Staphylococcus aureus</i> (+)	<i>Bacillus subtilis</i> (+)
5a	57.86 ± 0.70	68.05 ± 0.05	73.93 ± 0.13	36.85 ± 0.38	52.70 ± 0.63
5b	52.73 ± 0.68	57.30 ± 0.70	57.87 ± 0.09	57.14 ± 0.29	49.95 ± 0.66
5c	69.72 ± 0.45	59.05 ± 0.05	64.07 ± 0.00	58.67 ± 0.85	54.94 ± 0.63
5d	63.63 ± 0.15	52.85 ± 0.74	61.90 ± 0.37	23.80 ± 0.65	48.53 ± 0.12
5e	59.14 ± 1.00	53.75 ± 0.45	66.73 ± 0.90	62.90 ± 0.10	56.13 ± 0.27
5f	61.71 ± 0.40	43.60 ± 0.30	54.07 ± 0.81	39.33 ± 1.00	39.05 ± 0.31
Ciprofloxacin	91.05 ± 0.68	92.32 ± 0.42	92.02 ± 0.53	91.44 ± 0.64	92.50 ± 0.34

 TABLE-3
 MIC FOR ANTIBACTERIAL ACTIVITY OF SYNTHESIZED COMPOUNDS

Compounds	Inhibition (%)				
	<i>Salmonella typhi</i> (-)	<i>Escherichia coli</i> (-)	<i>Pseudomonas aeruginosa</i> (-)	<i>Staphylococcus aureus</i> (+)	<i>Bacillus subtilis</i> (+)
5a	15.98 ± 0.45	9.90 ± 0.13	18.99 ± 0.10	–	9.56 ± 0.78
5b	14.39 ± 0.31	17.54 ± 0.09	17.61 ± 0.24	14.59 ± 0.62	10.55 ± 0.52
5c	12.56 ± 0.87	–	–	–	17.78 ± 0.05
5d	11.62 ± 0.49	19.12 ± 0.89	–	–	12.98 ± 0.54
5e	9.90 ± 0.12	14.97 ± 0.56	17.89 ± 0.12	14.69 ± 0.76	11.67 ± 0.43
5f	17.43 ± 0.33	15.67 ± 0.34	–	16.78 ± 0.95	16.42 ± 0.12
Ciprofloxacin	7.45 ± 0.58	7.16 ± 0.58	7.29 ± 0.90	7.80 ± 0.19	7.14 ± 0.18

ciprofloxacin was $7.16 \pm 0.58 \mu\text{M}$. The compound **5f** showed moderate inhibition of all the microbes except *Pseudomonas aeruginosa*. The compound **5d** was active against three strains *Salmonella typhi*, *Escherichia coli* and *Bacillus subtilis*; whereas compound **5c** was active against only two strains, which are *Salmonella typhi* and *Bacillus subtilis*. If we take the antibacterial spectrum of these compounds into consideration, the compounds will have decreasing spectrum of antibacterial activity as **5e** > **5b** > **5a** > **5f** > **5d** > **5c**.

Compound **5b** bearing chlorinated aliphatic substituent was active against all bacterial strains under study but compound **5c** bearing brominated aliphatic substituent showed activity only against two bacterial strains. The results indicated that chloro group on aliphatic substituent had increased the spectrum of antibacterial activity of the synthesized. The antibacterial activity of compounds **5d** and **5e** indicated that the compounds bearing phenyl ring attached to smaller aliphatic chain were broad spectrum antibacterial agents.

Conclusion

The anticipated structures of compounds under study are supported and confirmed by spectroscopic data. Even though these compounds did not good enzyme inhibitors they are potent antibacterial agents. So these compounds, especially **5e** and **5b** can be considered for drug discovery and development program.

ACKNOWLEDGEMENTS

The authors are thankful to Higher Education Commission (HEC) of Pakistan for financial assistance. The authors are also thankful to Ministry of Higher Education (MOHE) under (FRGS) with sponsorship reference numbers FRGS/1/2016/TK10/UITM/02/3 and Universiti Teknologi MARA for the financial support under the reference number 600-RMI/FRGS 5/3 (0119/2016).

REFERENCES

- C.S. de-Oliveira, B.F. Lira, J.M. Barbosa-Filho, J.G.F. Lorenzo and P.F. de-Athayde-Filho, *Molecules*, **17**, 10192 (2012); <https://doi.org/10.3390/molecules170910192>.
- K. Al-Othman, M. Abdulla, B. Jeppsson, H. Asakawa, U. Srinivas and S. Bengmark, *Acta Pharm.*, **59**, 223 (2009); <https://doi.org/10.1111/j.1600-0773.1986.tb02749.x>.
- S.V. Bhandari, K.G. Bothara, M.K. Raut, A.A. Patil, A.P. Sarkate and V.J. Mokale, *Bioorg. Med. Chem. Lett.*, **16**, 1822 (2008); <https://doi.org/10.1016/j.bmc.2007.11.014>.
- G.A. Idrees, O.M. Aly, G.D. Abuo-Rahma and M.F. Radwan, *Eur. J. Med. Chem.*, **44**, 3973 (2009); <https://doi.org/10.1016/j.ejmech.2009.04.026>.
- V. Padmavathi, G. Sudhakar Reddy, A. Padmaja, P. Kondaiah and Ali-Shazia, *Eur. J. Med. Chem.*, **44**, 2106 (2009); <https://doi.org/10.1016/j.ejmech.2008.10.012>.
- H. Kumar, S.A. Javed, S.A. Khan and M. Amir, *Eur. J. Med. Chem.*, **43**, 2688 (2008); <https://doi.org/10.1016/j.ejmech.2008.01.039>.
- M.M. Burbuliene, V. Jakubkiene, G. Mekuskiene, E. Udrenaitė, R. Smicius and P. Vainilavicius, *Farmac.*, **59**, 767 (2004); <https://doi.org/10.1016/j.farmac.2004.05.007>.
- G.R. Bankar, G.K. Nampurath, P.G. Nayak and S. Bhattacharya, *Chem. Biol. Interact.*, **183**, 327 (2010); <https://doi.org/10.1016/j.cbi.2009.11.001>.
- Y. Shahar-Mohammad and A.W. Mohd, *Acta Pol. Pharm.*, **66**, 393 (2007).
- M. Akhter, A. Husain, B. Azad and M. Ajmal, *Eur. J. Med. Chem.*, **44**, 2372 (2009); <https://doi.org/10.1016/j.ejmech.2008.09.005>.
- O. Prakash, M. Kumar, R. Kumar, C. Sharma and K.R. Aneja, *Eur. J. Med. Chem.*, **45**, 4252 (2010); <https://doi.org/10.1016/j.ejmech.2010.06.023>.
- K. Matsumoto, Y. Kawamura, Y. Yasuda, T. Tanimoto, K. Matsumoto, T. Yoshida and J. Shoji, *J. Antibiot. (Tokyo)*, **42**, 1465 (1989); <https://doi.org/10.7164/antibiotics.42.1465>.
- A.A. Kadi, N.R. El-Brollosy, O.A. Al-Deeb, E.E. Habib, T.M. Ibrahim and A.A. El-Emam, *Eur. J. Med. Chem.*, **42**, 235 (2007); <https://doi.org/10.1016/j.ejmech.2006.10.003>.
- A. Mumtaz, Saeed and I. Malik, *J. Chem. Soc. Pak.*, **36**, 852 (2014).
- G.L. Ellman, K.D. Courtney, V. Andres Jr. and R.M. Featherstone, *Biochem. Pharmacol.*, **7**, 88 (1961); [https://doi.org/10.1016/0006-2952\(61\)90145-9](https://doi.org/10.1016/0006-2952(61)90145-9).
- P. Chapdelaine, R.R. Tremblay and J.Y. Dube, *Clin. Chem.*, **24**, 208 (1978).
- M. Kaspady, V.K. Narayanaswamy, M. Raju and G.K. Rao, *Lett. Drug Des. Discov.*, **6**, 21 (2009); <https://doi.org/10.2174/157018009787158481>.